1. Atherton, A., Busfield, D., and Hellmann, K., 1975, The effects of an antimetastatic agent, (±)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ICRF 159), on platelet behaviour. Cancer Research, 35, 953?957.
2. Bakowski, M. T., 1976, ICRF 159,(±) 1, 2-di(3,5-dioxopiperazin-1-yl)propane NSC-129,943; Razoxane. Cancer Treatment Reviews, 3, 95?107.
3. Bernardino, M. E., and Green, B., 1979, Ultrasonographic evaluation of chemo therapeutic response in hepatic metastases. Radiology, 33, 437?441.
4. Bernardino, M. E., and Lewis, E., 1982, Imaging hepatic neoplasms. Cancer, 50, 2666?2671.
5. Bellet, R. E., Engstrom, P. F., Catalano, R. B., Creech, R. H., and Mastrangelo, M. J., 1976, Phase II study of ICRF 159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treatment Reports, 60, 1395?1397.